CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AAML0431 | COG | The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| ARAR0332 | COG | Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| PBTC-051 | PBTC | Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | Pediatric CIRB | Available to Open |
| ACNS0222 | COG | A Phase II Study of Motexafin-Gadolinium (NSC #695238; IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| AEWS0521 | COG | A Randomized Phase II Study of Bevacizumab (NSC 704865; BB-IND# 7921) Combined with Vincristine; Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma | Pediatric CIRB | Completed |
| ACNS1021 | COG | A Phase II Study of Sunitinib (NSC# 736511; IND# 74019) in Recurrent; Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients | Pediatric CIRB | Completed |
| ANHL04B1 | COG | Rare and Cutaneous Non-Hodgkin Lymphoma Registry | Pediatric CIRB | Available to Open |
| ADVL1823 | COG | Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias | Pediatric CIRB | Available to Open |
| ARST0431 | COG | Intensive Multi-Agent Therapy; Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| AALL1131 | COG | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789; NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | Pediatric CIRB | Available to Open |